TY  - JOUR
AU  - Sautto, G.A.*
AU  - Diotti, R.A.*
AU  - Wisskirchen, K.
AU  - Kahle, K.M.*
C1  - 51598
C2  - 43267
CY  - London
TI  - New insights for immune-based diagnosis and therapy for infectious diseases.
JO  - J. Immunol. Res.
VL  - 2017
PB  - Hindawi Ltd
PY  - 2017
SN  - 2314-8861
ER  - 

TY  - JOUR
AB  - Interferon-α (IFN-α) has been used for more than 20 years as the first-line therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, because it has a number of antiviral effects. In this study, we describe a novel mode of its antiviral action. We demonstrate that the supernatant from IFN-α-treated cultured cells restricted HBV and HCV infection by inhibiting viral entry into hepatoma cells. The factors contained in the supernatant competed with the virus for binding to heparan glycosaminoglycans-the nonspecific attachment step shared by HBV and HCV. Secreted factors of high molecular mass that bind to heparin columns elicited the antiviral effect. In conclusion, IFN-α is able to induce soluble factors that can bind to heparan glycosaminoglycans thus leading to the inhibition of viral binding.
AU  - Xia, Y.
AU  - Cheng, X.
AU  - Blossey, C.K.
AU  - Wisskirchen, K.
AU  - Esser, K.
AU  - Protzer, U.
C1  - 50851
C2  - 42824
CY  - London
TI  - Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro.
JO  - J. Immunol. Res.
VL  - 2017
PB  - Hindawi Ltd
PY  - 2017
SN  - 2314-8861
ER  -